Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia

Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study (PART 1)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03024086

Enrollment

124

Registered

2017-01-18

Start date

2016-12-12

Completion date

2017-04-25

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Brief summary

The purpose of this study is to evaluate the Efficacy and Safety of DWJ1252 in treatment of Functional Dyspepsia.

Interventions

DRUGDWJ1252

DWJ1252 and Placebo of Gasmotin

DRUGGasmotin

Gasmotin and Placebo of DWJ1252

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male of female of at least 19 years old * Patient with functional dyspepsia met the ROME III criteria

Exclusion criteria

* Patients with previous gastrointestinal surgery * Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation * Patients with history of gastrointestinal cancer

Design outcomes

Primary

Measure	Time frame
The change from baseline in GIS (Gastrointestinal Symptom Score)	At 4 Weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026